AI Article Synopsis
- * Research combining various studies shows that this mutation enhances the opening of the virus’s receptor-binding domain (RBD) and slightly boosts binding to ACE2 compared to the original S:D614G variant.
- * Importantly, the S:A222V mutation does not decrease the neutralizing ability of antibodies from vaccinated individuals, indicating it likely does not affect the effectiveness of vaccines.
Article Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302720 | PMC |
| http://dx.doi.org/10.1371/journal.ppat.1010631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!